Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the Benzinga Biotech Small Cap Conference on March 25, 2021. CEO Dr. Robert Foster will provide a corporate overview at 9:45 a.m. Eastern Time, while Dr. Patrick Mayo will join a panel discussion on NASH treatments at 1:00 p.m. Eastern Time. The company's lead drug candidate, CRV431, targets non-alcoholic steatohepatitis (NASH) and demonstrates potential in reducing liver fibrosis and tumor burden in experimental models. Hepion also leverages its AI-POWR™ platform to optimize patient treatment outcomes.
- Hepion's lead drug candidate, CRV431, is in clinical-phase development targeting NASH and liver disease.
- CRV431 has shown potential to reduce liver fibrosis and tumor burden in experimental models.
- AI-POWR™ platform aims to identify NASH patients who will best respond to CRV431, potentially shortening development timelines.
- None.
EDISON, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced its participation in the Benzinga Biotech Small Cap Conference on Thursday, March 25, 2021. Details are as follows:
- Dr. Robert Foster, Hepion’s Chief Executive Officer, will present a corporate overview at 9:45 a.m. Eastern Time
- Dr. Patrick Mayo, the Company’s Senior Vice-President, Clinical Pharmacology and Analytics, will participate in the “NASH: The Race to Find a Treatment” panel at 1:00 p.m. Eastern Time
Individuals interested in attending the event can register online here.
About Hepion Pharmaceuticals
The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies.
Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.
For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com
FAQ
What event will Hepion Pharmaceuticals participate in on March 25, 2021?
What time will Dr. Robert Foster present at the Benzinga Conference?
What is CRV431 and what disease does it target?
How does Hepion use AI in drug development?
What is the focus of Dr. Patrick Mayo's panel discussion?
